Published online by Cambridge University Press: 19 October 2021
That people with chronic illness do not take all of their oral medications is well established, and schizophrenia is not unique in this regard. A World Health Organization study estimated that medication adherence among patients with chronic diseases averages only 50% in developed countries, with recent data indicating a rate of 45% for hypertension specifically [1, 2]. Unlike hypertension, where the impact of nonadherence might not be felt for years, poor adherence with oral antipsychotic therapy can result in psychotic relapse within days or weeks, leading to hospitalization, social disruption, and legal sequelae (e.g. increased risk for violence) [3, 4].